|
US5869451A
(en)
*
|
1995-06-07 |
1999-02-09 |
Glaxo Group Limited |
Peptides and compounds that bind to a receptor
|
|
US6251864B1
(en)
|
1995-06-07 |
2001-06-26 |
Glaxo Group Limited |
Peptides and compounds that bind to a receptor
|
|
KR100436680B1
(ko)
*
|
1995-06-07 |
2004-09-18 |
글락소 그룹 리미티드 |
트롬보포이에틴 수용체에 결합하는 펩티드 및 화합물
|
|
US7091311B2
(en)
|
1996-06-07 |
2006-08-15 |
Smithkline Beecham Corporation |
Peptides and compounds that bind to a receptor
|
|
US7083983B2
(en)
*
|
1996-07-05 |
2006-08-01 |
Cancer Research Campaign Technology Limited |
Inhibitors of the interaction between P53 and MDM2
|
|
JP2001521897A
(ja)
*
|
1997-10-31 |
2001-11-13 |
スミスクライン・ビーチャム・コーポレイション |
新規な金属錯体
|
|
AU748063B2
(en)
|
1997-10-31 |
2002-05-30 |
Ligand Pharmaceuticals Incorporated |
Novel metal complexes
|
|
AU738473B2
(en)
|
1997-10-31 |
2001-09-20 |
Glaxosmithkline Llc |
Novel metal complexes
|
|
US7153655B2
(en)
|
1998-06-16 |
2006-12-26 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
|
|
ATE348163T1
(de)
|
1998-10-23 |
2007-01-15 |
Amgen Inc |
Thrombopoietin substitute
|
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
AU3885901A
(en)
*
|
1999-09-21 |
2001-04-24 |
Emory University |
Methods and compositions for treating platelet-related disorders
|
|
US7332275B2
(en)
|
1999-10-13 |
2008-02-19 |
Sequenom, Inc. |
Methods for detecting methylated nucleotides
|
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
|
DE60035218D1
(de)
|
1999-11-18 |
2007-07-26 |
Dendreon Corp |
Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
|
|
TWI284639B
(en)
*
|
2000-01-24 |
2007-08-01 |
Shionogi & Co |
A compound having thrombopoietin receptor agonistic effect
|
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
|
AU2001259432B2
(en)
*
|
2000-05-03 |
2005-04-21 |
Amgen Inc. |
Modified peptides, comprising an FC domain, as therapeutic agents
|
|
US20050158838A1
(en)
*
|
2000-06-19 |
2005-07-21 |
Dyax Corp., A Delaware Corporation |
Novel enterokinase cleavage sequences
|
|
ES2316919T3
(es)
|
2000-12-05 |
2009-04-16 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos diseñados racionalmente.
|
|
US7396917B2
(en)
*
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
|
US6958213B2
(en)
|
2000-12-12 |
2005-10-25 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function
|
|
AU2002305052A1
(en)
|
2001-03-13 |
2002-09-24 |
Corvas International, Inc. |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
|
WO2002077263A2
(en)
|
2001-03-22 |
2002-10-03 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
|
|
US7105333B2
(en)
|
2001-03-27 |
2006-09-12 |
Deadreon Corporation |
Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
|
|
CA2447050A1
(en)
|
2001-05-14 |
2002-11-21 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
|
|
US7332474B2
(en)
*
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
|
US20030134794A1
(en)
*
|
2001-11-20 |
2003-07-17 |
Madison Edwin L. |
Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
|
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
|
EP1501863A4
(en)
|
2002-05-03 |
2007-01-24 |
Sequenom Inc |
KINASE ANCHOR PROTEIN, PEPTIDES AND RELATED METHODS THEREOF
|
|
EP1504098B2
(en)
|
2002-05-17 |
2011-02-09 |
Alligator Bioscience AB |
A method for in vitro molecular evolution of protein function
|
|
US7208594B2
(en)
*
|
2002-06-29 |
2007-04-24 |
Aquanova Ag |
Isoflavone concentrates as well as methods for their production
|
|
US20040028661A1
(en)
*
|
2002-08-07 |
2004-02-12 |
Bartelmez Stephen H. |
Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
|
|
EP1552828A4
(en)
|
2002-08-14 |
2007-01-24 |
Nissan Chemical Ind Ltd |
THROMBOPOIETIN RECEPTOR ACTIVATOR AND METHOD OF PRODUCTION
|
|
US7166574B2
(en)
*
|
2002-08-20 |
2007-01-23 |
Biosurface Engineering Technologies, Inc. |
Synthetic heparin-binding growth factor analogs
|
|
US7598224B2
(en)
*
|
2002-08-20 |
2009-10-06 |
Biosurface Engineering Technologies, Inc. |
Dual chain synthetic heparin-binding growth factor analogs
|
|
US8227411B2
(en)
*
|
2002-08-20 |
2012-07-24 |
BioSurface Engineering Technologies, Incle |
FGF growth factor analogs
|
|
CA2499625A1
(en)
*
|
2002-09-18 |
2004-04-01 |
Ortho-Mcneil Pharmaceutical, Inc. |
Methods of increasing platelet and hematopoietic stem cell production
|
|
TWI324593B
(en)
|
2002-10-09 |
2010-05-11 |
Nissan Chemical Ind Ltd |
Pyrazolone compounds and thrombopoietin receptor activator
|
|
JP2006522022A
(ja)
|
2003-02-14 |
2006-09-28 |
ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ |
プロテアソーム干渉に関連する避妊法および組成物
|
|
RS51130B
(sr)
*
|
2003-05-12 |
2010-10-31 |
Affymax Inc. |
Novi peptidi koji se vezuju za eritropoietinski receptor
|
|
CN1849141A
(zh)
|
2003-05-12 |
2006-10-18 |
阿费麦克斯公司 |
用于聚(乙二醇)修饰的肽的间隔臂部分
|
|
MXPA05012313A
(es)
*
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Peptidos que se unen al receptor de eritropoyetina.
|
|
DE602004028725D1
(de)
|
2003-05-12 |
2010-09-30 |
Affymax Inc |
Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
|
|
CN102796058B
(zh)
*
|
2003-08-12 |
2015-05-13 |
盐野义制药株式会社 |
具有血小板生成素受体激动作用的化合物
|
|
CN1871022B
(zh)
*
|
2003-08-28 |
2011-07-06 |
奥索-麦克尼尔药品公司 |
结合血小板生成素受体的肽和化合物
|
|
US7723295B2
(en)
*
|
2003-08-28 |
2010-05-25 |
Ortho-Mcneil Pharmaceutical, Inc. |
Peptides and compounds that bind to a receptor
|
|
ES2295961T3
(es)
|
2003-12-31 |
2008-04-16 |
F. Hoffmann-La Roche Ag |
Proceso para la sintesis peptidica utilizacndo una cantidad reducida de agente de desproteccion.
|
|
US7414028B1
(en)
*
|
2004-02-04 |
2008-08-19 |
Biosurface Engineering Technologies, Inc. |
Growth factor analogs
|
|
US20060024347A1
(en)
*
|
2004-02-10 |
2006-02-02 |
Biosurface Engineering Technologies, Inc. |
Bioactive peptide coatings
|
|
US7671012B2
(en)
|
2004-02-10 |
2010-03-02 |
Biosurface Engineering Technologies, Inc. |
Formulations and methods for delivery of growth factor analogs
|
|
US7528105B1
(en)
|
2004-02-10 |
2009-05-05 |
Biosurface Engineering Technologies |
Heterodimeric chain synthetic heparin-binding growth factor analogs
|
|
US20080227696A1
(en)
*
|
2005-02-22 |
2008-09-18 |
Biosurface Engineering Technologies, Inc. |
Single branch heparin-binding growth factor analogs
|
|
WO2005082005A2
(en)
|
2004-02-20 |
2005-09-09 |
Biosurface Engineering Technologies, Inc., Et Al. |
Positive modulator of bone morphogenic protein-2
|
|
CA2572765C
(en)
*
|
2004-07-08 |
2013-05-21 |
Amgen Inc. |
Compound having improved bioefficiency when administered in a multidose regimen
|
|
US20060210542A1
(en)
*
|
2004-08-16 |
2006-09-21 |
Yurkow Edward J |
Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
|
|
US7442778B2
(en)
*
|
2004-09-24 |
2008-10-28 |
Amgen Inc. |
Modified Fc molecules
|
|
US7589063B2
(en)
|
2004-12-14 |
2009-09-15 |
Aplagen Gmbh |
Molecules which promote hematopoiesis
|
|
AU2005310189A1
(en)
*
|
2004-11-11 |
2006-06-08 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
|
WO2006062240A1
(en)
|
2004-12-08 |
2006-06-15 |
Nissan Chemical Industries, Ltd. |
3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
|
|
TWI399368B
(zh)
|
2004-12-14 |
2013-06-21 |
Nissan Chemical Ind Ltd |
Amide compounds and thrombopoietin receptor activators
|
|
JP5517450B2
(ja)
|
2005-03-10 |
2014-06-11 |
バイオンテック アーゲー |
二量体または多量体のマイクロタンパク質
|
|
WO2006094530A1
(en)
*
|
2005-03-11 |
2006-09-14 |
Siegfried Ltd. |
Di-polymer protein conjugates and processes for their preparation
|
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
|
US7550433B2
(en)
*
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
|
EA200800109A1
(ru)
*
|
2005-06-23 |
2008-06-30 |
Аплаген Гмбх |
Суправалентные соединения
|
|
EP1904472A1
(en)
|
2005-07-15 |
2008-04-02 |
Nissan Chemical Industries, Ltd. |
Thiophene compounds and thrombopoietin receptor activators
|
|
KR101290484B1
(ko)
|
2005-07-20 |
2013-07-26 |
닛산 가가쿠 고교 가부시키 가이샤 |
피라졸 화합물 및 트롬보포이에틴 수용체 활성화제
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
US8026368B2
(en)
|
2005-11-07 |
2011-09-27 |
Nissan Chemical Industries, Ltd. |
Hydrazide compounds and thrombopoietin receptor activators
|
|
US7879318B2
(en)
|
2006-01-23 |
2011-02-01 |
Mcw Research Foundation, Inc. |
Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
|
|
US9012605B2
(en)
|
2006-01-23 |
2015-04-21 |
Amgen Inc. |
Crystalline polypeptides
|
|
EP1986677A2
(en)
*
|
2006-01-25 |
2008-11-05 |
Amgen Inc. |
Thrombopoietic compounds
|
|
EP1834963A1
(en)
*
|
2006-03-13 |
2007-09-19 |
Siegfried Ltd. |
Di-polymer protein conjugates and processes for their preparation
|
|
DE602007009954D1
(de)
|
2006-03-22 |
2010-12-02 |
Viral Logic Systems Technology |
Verfahren zur identifizierung von polypeptid-targets
|
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
|
US8377448B2
(en)
*
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
|
CA2652570A1
(en)
*
|
2006-05-15 |
2007-11-22 |
Viral Logic Systems Technology Corp. |
Cd47 related compositions and methods for treating immunological diseases and disorders
|
|
US7820172B1
(en)
|
2006-06-01 |
2010-10-26 |
Biosurface Engineering Technologies, Inc. |
Laminin-derived multi-domain peptides
|
|
EP2025671A4
(en)
|
2006-06-07 |
2011-04-06 |
Nissan Chemical Ind Ltd |
NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
|
|
US7981425B2
(en)
*
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
|
JP2009541358A
(ja)
|
2006-06-22 |
2009-11-26 |
バイオサーフェス エンジニアリング テクノロジーズ，インク． |
骨形成を強化するためにｂｍｐ−２増幅因子／共活性化因子を送達するための組成物および方法
|
|
WO2008051383A2
(en)
*
|
2006-10-19 |
2008-05-02 |
Amgen Inc. |
Use of alcohol co-solvents to improve pegylation reaction yields
|
|
WO2008095004A2
(en)
*
|
2007-01-31 |
2008-08-07 |
Affymax, Inc. |
Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
|
|
JP5591691B2
(ja)
|
2007-05-22 |
2014-09-17 |
アムジエン・インコーポレーテツド |
生物活性を有する融合タンパク質を作製するための組成物及び方法
|
|
US20090054332A1
(en)
*
|
2007-06-21 |
2009-02-26 |
Conjuchem Biotechnologies, Inc. |
Thombopoietin peptide conjugates
|
|
WO2009029682A1
(en)
*
|
2007-08-28 |
2009-03-05 |
Rigel Pharmaceuticals, Inc. |
Combination therapy with syk kinase inhibitor
|
|
US8183342B2
(en)
*
|
2007-11-06 |
2012-05-22 |
Case Western Reserve University |
Method of treating chemotherapy-induced thrombocytopenia
|
|
CN101481352A
(zh)
|
2008-01-10 |
2009-07-15 |
上海恒瑞医药有限公司 |
双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
|
|
EP2247618B1
(en)
|
2008-01-25 |
2014-06-11 |
Amgen, Inc |
Ferroportin antibodies and methods of use
|
|
ES2487846T3
(es)
|
2008-05-01 |
2014-08-25 |
Amgen, Inc. |
Anticuerpos anti-hepcindina y métodos de uso
|
|
CA2755336C
(en)
|
2009-03-20 |
2015-07-14 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
|
WO2011012306A2
(en)
|
2009-07-30 |
2011-02-03 |
Aplagen Gmbh |
Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
|
|
EP2492262B1
(en)
|
2009-10-23 |
2016-04-20 |
Nissan Chemical Industries, Ltd. |
Fused heterocyclic compound and thrombopoietin receptor activator
|
|
WO2011098095A1
(en)
|
2010-02-09 |
2011-08-18 |
Aplagen Gmbh |
Peptides binding the tpo receptor
|
|
MX383982B
(es)
|
2010-09-22 |
2025-03-14 |
Amgen Inc |
Inmunoglobulinas portadoras y usos de las mismas.
|
|
WO2014159242A1
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Notch 3 mutants and uses thereof
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
EA034496B1
(ru)
|
2014-09-11 |
2020-02-13 |
Бристол-Майерс Сквибб Компани |
Макроциклические ингибиторы белок/белковых взаимодействий pd-1/pd-l1 и cd80(b7-1)/pd-l1
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
BR112017010268B1
(pt)
|
2014-11-19 |
2024-01-16 |
P & M Venge Ab |
Agente de ligação, composição de diagnóstico, kit de diagnóstico, método de diagnóstico de uma infecção bacteriana ou de diferenciação entre uma infecção bacteriana e uma infecção de viral, métodos para descartar uma infecção bacteriana ou viral em um indivíduo, métodos para considerar uma infecção bacteriana ou viral em um indivíduo, método para distinguir entre uma infecção bacteriana ou mista e uma infecção viral em um indivíduo, método para descartar uma doença infecciosa, método para identificação do tipo de infecção e dispositivo para o diagnóstico de infecções bacterianas
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
MX2018014028A
(es)
|
2016-05-19 |
2019-04-04 |
Squibb Bristol Myers Co |
Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet).
|
|
WO2018085750A2
(en)
|
2016-11-07 |
2018-05-11 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
CN110997698B
(zh)
|
2017-06-23 |
2023-12-26 |
百时美施贵宝公司 |
充当pd-1拮抗剂的免疫调节剂
|
|
JP7481252B2
(ja)
*
|
2017-07-26 |
2024-05-10 |
ヤンセン ファーマシューティカ エヌ．ベー． |
標的放射線治療誘発性血管完全性を保護する方法
|
|
EP3692053A1
(en)
|
2017-10-03 |
2020-08-12 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
AU2020273115A1
(en)
|
2019-01-25 |
2021-08-12 |
Janssen Pharmaceutica Nv |
Methods of mitigating toxic effects of vesicants and caustic gas
|
|
AU2020210869A1
(en)
|
2019-01-25 |
2021-08-19 |
Janssen Pharmaceutica Nv |
Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
|
|
MA54820A
(fr)
*
|
2019-01-25 |
2021-12-01 |
Janssen Pharmaceutica Nv |
Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
|
|
KR20220122752A
(ko)
|
2020-01-06 |
2022-09-02 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제
|
|
KR20220161407A
(ko)
|
2020-03-30 |
2022-12-06 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제
|
|
US20230104658A1
(en)
|
2021-10-01 |
2023-04-06 |
Janssen Pharmaceutica Nv |
Methods of increasing progenitor cell production
|
|
WO2024095178A1
(en)
|
2022-11-01 |
2024-05-10 |
Janssen Pharmaceutica Nv |
Thrombopoietin mimetic for use in the treatment of acute liver failure
|